Core Viewpoint - Tango Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 4, 2025, at 9:00 am ET, prior to the opening of U.S. financial markets, and will not hold a conference call [1] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2]

Core Viewpoint - Tango Therapeutics, Inc. (TNGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The upgrade reflects an improvement in Tango Therapeutics' underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, Tango Therapeutics is expected to earn -$1.05 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 23.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - The upgrade to Zacks Rank 2 places Tango Therapeutics in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Points - Tango Therapeutics held a conference call to discuss clinical data related to vopimetostat [2][3] - The call featured presentations from key executives including Dr. Barbara Weber and Dr. Adam Crystal, with a Q&A session to follow [3] Company Overview - The conference was led by Liz Hickin, VP of Investor Relations and Corporate Communications, indicating the company's focus on investor engagement [2][3] - The press release regarding the clinical data was made available on the company's website, highlighting transparency and communication with stakeholders [3] Leadership Involvement - Dr. Barbara Weber, President and CEO, and Dr. Adam Crystal, President of R&D, were key speakers during the call, emphasizing the importance of leadership in discussing clinical advancements [3] - CFO Daniella Beckman joined the Q&A session, indicating a comprehensive approach to addressing investor inquiries [3]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

Core Insights - Tango Therapeutics Inc. has reported data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers, indicating a promising efficacy profile [1] Efficacy Results Across Study Indications - As of September 1, 2025, 179 patients were enrolled across all cancer types, with 154 receiving active doses of 200 mg and above - The overall response rate (ORR) across cancer types was 27%, with a disease control rate (DCR) of 78% and a median progression-free survival (mPFS) of 6.4 months [2] Efficacy Results in Pancreatic Cancer Patients - Among 64 patients with pancreatic cancer, 39 received active doses, showing an ORR of 25% in second-line patients and 15% in all pancreatic cancer patients - The DCR for all pancreatic cancer patients was 71%, with mPFS of 7.2 months in second-line patients and 4.1 months in third-line and above patients [7] Development Strategy in Pancreatic Cancer - The company plans to initiate a global, randomized, pivotal study in 2026, enrolling approximately 300 patients with MTAP-deleted pancreatic cancer who have received one prior line of therapy, comparing vopimetostat to standard chemotherapy regimens [3][4] Enrollment in Lung Cancer - As of September 1, 2025, 41 patients with second-line or higher lung cancer were enrolled, with 12 receiving active doses; a safety and efficacy update is expected in 2026 [5] Financial Actions - Tango Therapeutics has priced an underwritten offering of 21.02 million shares and pre-funded warrants to purchase up to 3.23 million shares at $8.66, expecting gross proceeds of approximately $210 million [5] Price Action - TNGX stock experienced a decline of 14.78%, trading at $7.38 [6]

Summary of Tango Therapeutics Conference Call on VOCA Medi-Stat Clinical Data Company Overview - **Company**: Tango Therapeutics (NasdaqGM:TNGX) - **Focus**: Development of cancer drugs targeting genes frequently deleted in human cancers, specifically through the concept of synthetic lethality [3][22] Key Points on VOCA Medi-Stat - **Drug Name**: VOCA Medi-Stat (formerly TNG462) - **Mechanism**: PRNP-5 inhibitor designed for cancers with MTAP deletion, sparing normal cells [3][4] - **Target Population**: Approximately 60,000 patients annually in the U.S. with MTAP-deleted solid tumors, including pancreatic and lung cancers [5][6] Clinical Development - **Initial Focus**: Pancreatic cancer, with 20,000 MTAP-deleted cases annually in the U.S. [4] - **Pivotal Study Plans**: First pivotal study planned for 2026 in second-line MTAP-deleted pancreatic cancer [4][22] - **Combination Trials**: Ongoing trials combining VOCA Medi-Stat with RAS inhibitors (daraxonrasib and zoldonrasib) to explore chemotherapy-free treatment options [4][17] Clinical Data Highlights - **Overall Response Rate**: 27% across all patients, with a median progression-free survival (PFS) of 6.4 months [9][11] - **Second-Line Pancreatic Cancer**: Median PFS of 7.2 months and overall response rate of 25%, significantly better than historical standards of care [9][15] - **Histology-Agnostic Cohort**: Overall response rate of 49% with a median PFS of 9.1 months, indicating strong activity across multiple cancer types [19][20] Safety and Tolerability - **Safety Profile**: Best-in-class safety profile with no drug-related discontinuations and a low dose reduction rate of 8% [9][12] - **Adverse Events**: Most adverse events were grade 1, with no grade 4 or 5 events reported [12][21] - **Dosing Strategy**: Optimized dosing at 250 mg daily, balancing efficacy and tolerability [12][60] Future Outlook - **Upcoming Data Releases**: Strong cadence of disclosures planned for 2026, including updates on combination studies and initial data from first-line pancreatic cancer cohorts [8][20] - **Market Positioning**: VOCA Medi-Stat positioned to be the first MTAP-selective PRNP-5 inhibitor to market, with significant potential in multiple cancer types [20][22] Additional Considerations - **Regulatory Interactions**: Plans for FDA interactions regarding pivotal study design and control regimens [27][45] - **Screening Rates**: Estimated MTAP deletion screening rate in the U.S. is about 40%, with ongoing efforts to improve this for better patient enrollment [52][56] - **Companion Diagnostics**: Development of companion diagnostics for rapid MTAP deletion screening to facilitate patient enrollment [56] This summary encapsulates the critical insights from the conference call regarding Tango Therapeutics' VOCA Medi-Stat, highlighting its clinical development, safety profile, and future plans in the oncology landscape.

Vopimetostat (TNG462) Overview - Vopimetostat is an oral, once-a-day, MTAP-selective PRMT5 inhibitor with a potential best-in-class safety profile[7] - Key indications for development include pancreatic cancer (~20,000 patients/yr), lung cancer (~22,000 patients/yr), and histology agnostic cancers (~20,000 patients/yr) in the US[7] - A pivotal study in second-line (2L) pancreatic cancer is planned to initiate in 2026, with the potential to be first-to-market in 2L MTAP-del pancreatic cancer[7] Clinical Trial Data and Efficacy - Vopimetostat demonstrated an overall response rate (ORR) of 27% across cancer types, suggesting it could be best-in-class[13,16,18] - In 2L MTAP-del pancreatic cancer, the median progression-free survival (mPFS) was 7.2 months, with an ORR of 25%, supporting the planned pivotal study start in 2026[13,34] - The histology agnostic cohort (excluding sarcoma, pancreatic, and lung cancer) showed a 49% ORR and an mPFS of 9.1 months[13,51,53] Safety and Tolerability - Vopimetostat has a potential best-in-class safety and tolerability profile, with approximately 8% dose reduction and no drug-related dose discontinuations[13,25] Combination Studies and Future Plans - Ongoing combination study of vopimetostat + RAS(ON) inhibitors in 2L+ MTAP-del pancreatic and lung cancer patients, with expansion to first line (1L) cohort planned[13,43,45] - Lung cancer cohort is fully enrolled (n=41), with an update planned for 2026[13,48]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 108% to $8.05 - Brera Holdings PLC (SLMT) rose by 49% to $12.50 - Safe & Green Holdings Corp. (SGBX) gained 39% to $3.18 - American Rebel Holdings, Inc. (AREB) up by 26% to $2.71 - Tango Therapeutics, Inc. (TNGX) increased by 18% to $10.25 - Garrett Motion Inc. (GTX) rose by 14% to $14.30 - ETHZilla Corporation (ETHZ) gained 12% to $17.61 - D-Wave Quantum Inc. (QBTS) increased by 11% to $30.40 - IonQ, Inc. (IONQ) rose by 10% to $61.04 - Megan Holdings Limited (MGN) up by 7% to $2.31 [3] Premarket Losers - Splash Beverage Group, Inc. (SBEV) decreased by 21% to $2.06 - Molina Healthcare, Inc. (MOH) down by 18% to $158.44 - SCHMID Group N.V. (SHMD) fell by 18% to $3.18 - Beyond Meat, Inc. (BYND) decreased by 18% to $2.91 - Agencia Comercial Spirits Ltd (AGCC) down by 16% to $5.07 - Super League Enterprise, Inc. (SLE) fell by 13% to $2.25 - Armata Pharmaceuticals, Inc. (ARMP) decreased by 12% to $5.99 - Applied DNA Sciences, Inc. (BNBX) down by 12% to $4.19 - Ribbon Communications Inc. (RBBN) fell by 12% to $3.49 - Tamboran Resources Corporation (TBN) decreased by 11% to $21.81 [4]

Core Viewpoint - Tango Therapeutics, Inc. has announced a significant underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $210 million to support its precision cancer medicine initiatives [1] Group 1: Offering Details - The offering consists of 21,023,337 shares of common stock priced at $8.66 each and pre-funded warrants to purchase up to 3,226,458 shares priced at $8.659 [1] - The gross proceeds from the offering are expected to be around $210 million before deducting underwriting discounts and commissions [1] - The offering is anticipated to close on or about October 24, 2025, subject to customary closing conditions [1] Group 2: Private Investment in Public Equity (PIPE) - Concurrently, Tango has entered into a PIPE agreement, selling 1,732,101 shares at the same price of $8.66 per share, expected to generate approximately $15 million [3] - The PIPE is also expected to close on or about October 24, 2025, subject to customary closing conditions [3] Group 3: Management and Regulatory Information - Leerink Partners and Cantor are acting as joint bookrunning managers for the offering [2] - The offering is made under an effective shelf registration statement previously filed with the SEC, and related documents will be available on the SEC's website [4]

Core Viewpoint - Tango Therapeutics, Inc. has announced a significant underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $210 million to support its precision cancer medicine initiatives [1] Group 1: Offering Details - The offering consists of 21,023,337 shares of common stock priced at $8.66 each and pre-funded warrants to purchase up to 3,226,458 shares priced at $8.659 each [1] - The gross proceeds from the offering are expected to be around $210 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about October 24, 2025, subject to customary closing conditions [1] Group 2: Private Investment in Public Equity (PIPE) - Concurrently, Tango has entered into a PIPE agreement, selling 1,732,101 shares at the same price of $8.66 per share, with expected gross proceeds of approximately $15 million [3] - The PIPE is led by Nextech and is also expected to close on or about October 24, 2025, subject to customary closing conditions [3] Group 3: Management and Regulatory Information - Leerink Partners and Cantor are acting as joint bookrunning managers for the offering [2] - The offering is made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4] - The securities sold in the PIPE are not registered under the Securities Act of 1933 and will require a registration statement for resale [5] Group 4: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [7] - The company utilizes the genetic principle of synthetic lethality to target critical areas in cancer, including tumor suppressor gene loss [7]